Experts Predict FHLC Will Hit $81
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: NASDAQ.COM
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRMD
Wall Street analysts forecast IRMD stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 92.050
Low
98.00
Averages
99.00
High
100.00
Current: 92.050
Low
98.00
Averages
99.00
High
100.00
About IRMD
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IRADIMED CEO Sells 7,500 Shares Indirectly
- Transaction Overview: Roger E. Susi, CEO of IRADIMED, indirectly sold 7,500 shares of common stock between May 26 and 27, 2026, totaling approximately $691,000, aligning with his historical sales pattern averaging between 5,000 and 10,000 shares over the past year.
- Holding Changes: Post-transaction, Susi's Phillip Susi 2008 Dynasty Trust retains about 2.165 million shares, indicating a continued reduction in his indirect holdings, with no direct ownership or outstanding options remaining after the sale.
- Market Context: The sale occurred during a period when IRADIMED posted a 77.2% total return over the past year, with the sale price near recent highs, suggesting a systematic liquidation rather than discretionary trading.
- Investor Implications: IRADIMED focuses on MRI-compatible medical devices, addressing safety issues with standard IV pumps in MRI suites; while the CEO's trust sales do not alter the investment fundamentals, the acceptance of new products will be a key variable for investors moving forward.
See More
Iradimed CEO Sells 7,500 Shares of Stock
- Executive Stock Sale: Iradimed CEO Roger E. Susi indirectly sold 7,500 shares on May 26 and 27, 2026, through the Phillip Susi 2008 Dynasty Trust, with a transaction value of approximately $691,000, representing 0.35% of his total pre-transaction holdings.
- Transaction Price Analysis: The sale was executed at a weighted average price of $92.14 per share, yet post-transaction, the stock closed at $0.00 on May 27, 2026, indicating significant market volatility surrounding the stock.
- Market Competitive Position: Iradimed focuses on manufacturing MRI-compatible equipment, addressing the safety concerns of standard IV pumps and patient monitors in MRI suites, thereby establishing a unique competitive advantage in the medical device sector.
- Future Growth Potential: While the CEO's trust sales have not altered the fundamental investment outlook, the adoption of the new infusion pump won't be evident until mid-2027, prompting investors to monitor this product cycle's performance to assess future revenue growth.
See More
Iradimed Founder Sells 7,500 Shares in Strategic Move
- Sale Overview: Roger Susi, founder and CEO of Iradimed, sold 7,500 shares between May 18 and 19, 2026, at a weighted average price of approximately $87.64, totaling around $657,000, which represents 0.17% of his total holdings.
- Holding Analysis: After the transaction, Susi retains 4,397,950 indirect shares, indicating his continued confidence in the company, and this sale is part of a multi-year programmatic reduction in indirect holdings, reflecting his keen awareness of market dynamics.
- Trading Plan Context: The share sale was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025, aimed at avoiding accusations of insider trading, which underscores the compliance and transparency of his transactions.
- Company Performance: Iradimed reported $22 million in revenue for Q1 2026, a 13% year-over-year increase, while diluted earnings per share rose 22% to $0.45, demonstrating strong performance in the medical device sector and further bolstering investor confidence.
See More
Iradimed Founder Indirectly Sells 7,500 Shares
- Transaction Overview: Roger E. Susi, Founder and CEO of Iradimed, indirectly sold 7,500 shares of common stock on May 18 and 19, 2026, for approximately $657,000, leaving him with 4,397,950 shares, indicating confidence in the company's future.
- Historical Trading Pattern: The sale of 7,500 shares aligns with Susi's historical trading cadence, averaging 21.6 trades per year with typical sell tranches between 5,000 and 10,000 shares, reflecting a consistent divestment strategy since May 2023.
- Company Financial Performance: As of May 2026, Iradimed reported a trailing twelve-month revenue of $86.28 million and a net income of $23.61 million, with a stock price increase of 82.77% over the past year, showcasing strong growth in the medical device sector.
- Investor Confidence: This transaction was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025 to avoid insider trading allegations, and with over 4 million shares retained post-sale, it underscores his ongoing confidence in the company's prospects.
See More
IRADIMED Reports 13% Revenue Growth in Q1 2026
- Financial Performance Boost: IRADIMED reported Q1 2026 revenue of $21.98 million, reflecting a 13% increase, with net income reaching $5.82 million and earnings per share of $0.45, showcasing strong performance in the MRI-compatible medical device market.
- Adjusted Earnings Growth: The adjusted net income stood at $6.36 million, or $0.49 per share, compared to $5.34 million and $0.42 per share in the prior year, indicating sustained improvement in profitability and bolstering investor confidence.
- Optimistic Future Outlook: The company expects Q2 2026 revenue between $20.0 million and $21.0 million, with diluted earnings per share projected at $0.40 to $0.44, and adjusted earnings per share at $0.44 to $0.48, reflecting stable growth potential.
- Dividend Distribution Plan: IRADIMED declared a quarterly cash dividend of $0.20 per share, payable on May 29, 2026, which enhances shareholder returns and reflects the company's confidence in future cash flows.
See More
Iradimed Surges 4.45% After Strong Quarterly Earnings Beat Expectations
- Significant Revenue Growth: Iradimed's first-quarter revenue increased by 13% to nearly $22 million, surpassing analyst expectations of $20.8 million, indicating strong performance in the MRI equipment market.
- Improved Profitability: The company's net income rose by 24% to over $5.8 million, with non-GAAP earnings per share increasing by 17% to $0.49, both exceeding market forecasts and reflecting ongoing improvements in profitability.
- Successful Product Launch: The new IV pump system, model 3870, was commercially launched during the quarter, with the CEO noting encouraging customer reception and strong early order activity, suggesting significant future sales potential.
- Optimistic Outlook: Iradimed maintained its revenue guidance of $91 million to $96 million and adjusted earnings per share forecast of $2.06 to $2.21, demonstrating confidence in future growth, particularly as aging populations drive increased demand for medical care.
See More
IRADIMED CEO Sells 7,500 Shares Indirectly
- Transaction Overview: Roger E. Susi, CEO of IRADIMED, indirectly sold 7,500 shares of common stock between May 26 and 27, 2026, totaling approximately $691,000, aligning with his historical sales pattern averaging between 5,000 and 10,000 shares over the past year.
- Holding Changes: Post-transaction, Susi's Phillip Susi 2008 Dynasty Trust retains about 2.165 million shares, indicating a continued reduction in his indirect holdings, with no direct ownership or outstanding options remaining after the sale.
- Market Context: The sale occurred during a period when IRADIMED posted a 77.2% total return over the past year, with the sale price near recent highs, suggesting a systematic liquidation rather than discretionary trading.
- Investor Implications: IRADIMED focuses on MRI-compatible medical devices, addressing safety issues with standard IV pumps in MRI suites; while the CEO's trust sales do not alter the investment fundamentals, the acceptance of new products will be a key variable for investors moving forward.
See More
Iradimed CEO Sells 7,500 Shares of Stock
- Executive Stock Sale: Iradimed CEO Roger E. Susi indirectly sold 7,500 shares on May 26 and 27, 2026, through the Phillip Susi 2008 Dynasty Trust, with a transaction value of approximately $691,000, representing 0.35% of his total pre-transaction holdings.
- Transaction Price Analysis: The sale was executed at a weighted average price of $92.14 per share, yet post-transaction, the stock closed at $0.00 on May 27, 2026, indicating significant market volatility surrounding the stock.
- Market Competitive Position: Iradimed focuses on manufacturing MRI-compatible equipment, addressing the safety concerns of standard IV pumps and patient monitors in MRI suites, thereby establishing a unique competitive advantage in the medical device sector.
- Future Growth Potential: While the CEO's trust sales have not altered the fundamental investment outlook, the adoption of the new infusion pump won't be evident until mid-2027, prompting investors to monitor this product cycle's performance to assess future revenue growth.
See More
Iradimed Founder Sells 7,500 Shares in Strategic Move
- Sale Overview: Roger Susi, founder and CEO of Iradimed, sold 7,500 shares between May 18 and 19, 2026, at a weighted average price of approximately $87.64, totaling around $657,000, which represents 0.17% of his total holdings.
- Holding Analysis: After the transaction, Susi retains 4,397,950 indirect shares, indicating his continued confidence in the company, and this sale is part of a multi-year programmatic reduction in indirect holdings, reflecting his keen awareness of market dynamics.
- Trading Plan Context: The share sale was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025, aimed at avoiding accusations of insider trading, which underscores the compliance and transparency of his transactions.
- Company Performance: Iradimed reported $22 million in revenue for Q1 2026, a 13% year-over-year increase, while diluted earnings per share rose 22% to $0.45, demonstrating strong performance in the medical device sector and further bolstering investor confidence.
See More
Iradimed Founder Indirectly Sells 7,500 Shares
- Transaction Overview: Roger E. Susi, Founder and CEO of Iradimed, indirectly sold 7,500 shares of common stock on May 18 and 19, 2026, for approximately $657,000, leaving him with 4,397,950 shares, indicating confidence in the company's future.
- Historical Trading Pattern: The sale of 7,500 shares aligns with Susi's historical trading cadence, averaging 21.6 trades per year with typical sell tranches between 5,000 and 10,000 shares, reflecting a consistent divestment strategy since May 2023.
- Company Financial Performance: As of May 2026, Iradimed reported a trailing twelve-month revenue of $86.28 million and a net income of $23.61 million, with a stock price increase of 82.77% over the past year, showcasing strong growth in the medical device sector.
- Investor Confidence: This transaction was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025 to avoid insider trading allegations, and with over 4 million shares retained post-sale, it underscores his ongoing confidence in the company's prospects.
See More
IRADIMED Reports 13% Revenue Growth in Q1 2026
- Financial Performance Boost: IRADIMED reported Q1 2026 revenue of $21.98 million, reflecting a 13% increase, with net income reaching $5.82 million and earnings per share of $0.45, showcasing strong performance in the MRI-compatible medical device market.
- Adjusted Earnings Growth: The adjusted net income stood at $6.36 million, or $0.49 per share, compared to $5.34 million and $0.42 per share in the prior year, indicating sustained improvement in profitability and bolstering investor confidence.
- Optimistic Future Outlook: The company expects Q2 2026 revenue between $20.0 million and $21.0 million, with diluted earnings per share projected at $0.40 to $0.44, and adjusted earnings per share at $0.44 to $0.48, reflecting stable growth potential.
- Dividend Distribution Plan: IRADIMED declared a quarterly cash dividend of $0.20 per share, payable on May 29, 2026, which enhances shareholder returns and reflects the company's confidence in future cash flows.
See More
Iradimed Surges 4.45% After Strong Quarterly Earnings Beat Expectations
- Significant Revenue Growth: Iradimed's first-quarter revenue increased by 13% to nearly $22 million, surpassing analyst expectations of $20.8 million, indicating strong performance in the MRI equipment market.
- Improved Profitability: The company's net income rose by 24% to over $5.8 million, with non-GAAP earnings per share increasing by 17% to $0.49, both exceeding market forecasts and reflecting ongoing improvements in profitability.
- Successful Product Launch: The new IV pump system, model 3870, was commercially launched during the quarter, with the CEO noting encouraging customer reception and strong early order activity, suggesting significant future sales potential.
- Optimistic Outlook: Iradimed maintained its revenue guidance of $91 million to $96 million and adjusted earnings per share forecast of $2.06 to $2.21, demonstrating confidence in future growth, particularly as aging populations drive increased demand for medical care.
See More
